Cambrian BioPharma

United States - New York, New York

• 26/10/2021
• Series C
• $100,000,000

Cambrian BioPharma is building the medicines that will modernize healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health.

As a Distributed Development Company (or DisCo), Cambrian is advancing multiple scientific breakthroughs, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve quality of life/overall quality of life as we age.

Related People

James Peyer, PhDFounder

United States - New York City Metropolitan Area

As Founder and CEO of Cambrian Bio, a Distributed Drug Development Company (or a "DisCo" as we like to call it), I’m focused on developing therapeutics targeting the biological drivers of aging. Cambrian builds, directs, operates, and finances a pipeline of therapeutics. I founded the company to translate laboratory breakthroughs in the extension of healthy lifespan into the clinic, because the world is entering a revolution in medical research that will change our relationship with medicines from REactive to PROactive. Learn more: www.cambrianbio.com

Before Cambrian, I started Apollo Ventures, the first company builder in Longevity Therapeutics, where I was founder, investor, and CEO of multiple companies. I did my PhD with a focus on blood stem cell biology as a National Science Foundation Fellow at UT Southwestern.

LinkedIn https://www.linkedin.com/in/jamespeyer/